US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.54

+0.11220.39%

Volume:409

Turnover:11.67K

Market Cap:2.57M

PE:- -

High:28.54

Open:28.54

Low:28.54

Close:28.43

52wk High:28.93

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.41

T/O Rate:0.45%

Dividend:0.92

Dividend Rate:3.22%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

JPMorgan SMid biotech analysts hold an analyst/industry conference call

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

Veeva supporting transformation of medicine through AI, Barron’s reports

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

RYUK-IL C&S pivots to biotech and pet markets with sweeping charter changes

Corvus announces initiation of Phase 1b clinical trial of soquelitinib

Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Satellos announces enrollment completed for BASECAMP

Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic”

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo

New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety

CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.54,"timestamp":1790880797021,"preClose":28.4278,"halted":0,"volume":409,"delay":0,"changeRate":0.003946840768543392,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0.1122,"latestTime":"10-01 14:56:59 EDT","open":28.54,"high":28.54,"low":28.54,"amount":11671.227681,"amplitude":0,"askPrice":28.85,"askSize":100,"bidPrice":28.78,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.4278,"nav":28.36,"aum":2552427.21,"dividendRate":0.032172,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.4278,"latestTime":"16:10 EDT","volume":6,"amount":170.5668,"timestamp":1790799005215,"change":0.1822,"changeRate":0.006409,"amplitude":0},"volumeRatio":0.413458},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.413458,"shares":90001,"dividePrice":0.9182,"high":28.54,"amplitude":0,"preClose":28.4278,"low":28.54,"week52Low":24.54,"pbRate":"--","week52High":28.93,"institutionHeld":0,"latestPrice":28.54,"eps":0,"divideRate":0.032172,"volume":409,"delay":0,"ttmEps":0,"open":28.54,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":27.9349,"twentyDayClose":27.8834},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672662237","title":"JPMorgan SMid biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672662237","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672662237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:50","pubTimestamp":1790873411,"startTime":"0","endTime":"0","summary":"SMid Biotechnology Analysts Cheng and Medeiros discuss their view on Kymera Therapeutics’s (KYMR) STATS readout in atopic dermatitis on an Analyst/...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000BZT7R73.USD","LU0238689110.USD","LU2054465674.USD","LU0234572021.USD","IE00BZ1G4Q59.USD","FTXO","IE00BJTD4V19.USD","LU0320765489.SGD","LU2357627491.SGD","LU0256863902.USD","IE00BN8TJ469.HKD","LU1244550577.SGD","VFH","BK4585","LU2168564222.USD","IE00BFXG1179.USD","KYMR","FNCL","IXG","LU0106831901.USD","LU0971096721.USD","LU2213496289.HKD","LU1917777945.USD","IE00B3S45H60.SGD","LU2552382132.HKD","KBWB","LU0265550946.USD","LU0943347566.SGD","LU2505996509.AUD","SG9999002224.SGD","TFNS","UYG","IYG","LU2168563687.JPY","BK4139","LU1064131342.USD","BK4207","JPO","TRUF","LU0820562030.AUD","IYF","JPM","NVIB","PGF","XLF","LU2236285917.USD","JPMO","XBIX","LU0211326755.USD","LU0345769631.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750336","title":"AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750336","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750336?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:02","pubTimestamp":1790859720,"startTime":"0","endTime":"0","summary":"Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC programOCALA, Fla., Oct.  01,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372985/29489/en/aim-immunotech-spotlights-growing-attention-around-ampligen-pancreatic-cancer-strategy-as-duripanc-advances-toward-topline-data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","MEDX","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672579387","title":"Veeva supporting transformation of medicine through AI, Barron’s reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2672579387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672579387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:55","pubTimestamp":1790859332,"startTime":"0","endTime":"0","summary":"AI holds the promise to accelerate drug development, optimize clinical trials, and bring lifesaving therapies to market faster, and Veeva (VEEV) Sy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","BK4534","LU0058720904.USD","VEEV","AGIX","VTHR","LU0106261372.USD","LU1989764748.USD","AIPO","EKG","BK4504","GDOC","ARTY","QTOC","LFSC","FBT","BK4588","BK4613","LU1989764664.SGD","LU0170899867.USD","LU0289739699.SGD","NVIB","BMED","MEDX","LGHT","BK4585","LU0006306889.USD","CHAT","IDNA","BK4528","HYLG","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759490","title":"Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759490","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759490?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851500,"startTime":"0","endTime":"0","summary":"- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372706/0/en/kailera-therapeutics-presents-new-clinical-data-at-easd-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","IDNA","MEDX","BK4139","JDOC","KLRA","OZEM","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672739201","title":"RYUK-IL C&S pivots to biotech and pet markets with sweeping charter changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672739201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672739201?lang=en_us&edition=fundamental","pubTime":"2026-10-01 11:12","pubTimestamp":1790824358,"startTime":"0","endTime":"0","summary":"RYUK-IL C&S., Ltd. ( ($KR:191410) ) has provided an announcement. RYUK-IL C&S., Ltd. shareholders approved a partial amendment of the Articles of I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ryuk-il-cs-pivots-to-biotech-and-pet-markets-with-sweeping-charter-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ryuk-il-cs-pivots-to-biotech-and-pet-markets-with-sweeping-charter-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782978","title":"Corvus announces initiation of Phase 1b clinical trial of soquelitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782978?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:10","pubTimestamp":1790799031,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals (CRVS) announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corvus-announces-initiation-of-phase-1b-clinical-trial-of-soquelitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corvus-announces-initiation-of-phase-1b-clinical-trial-of-soquelitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","IDNA","BK4568","BK4139","HYLG","GDOC","MEDX","CRVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671207502","title":"Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2671207502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671207502?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:14","pubTimestamp":1790774085,"startTime":"0","endTime":"0","summary":"Connect Biopharma stock rallied over 98% after the company announced new clinical trial data for rademikibart.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-connect-biopharma-cntb-up-98-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-connect-biopharma-cntb-up-98-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["82822","MEDX","NVIB","FXP","82823","CWEB","CHAU","02843","KBA","HYLG","ASHS","XPP","02823","YXI","YINN","82843","GDOC","KWEB","FLCH","YANG","KCAI","ASHR","BK4139","CNTB","02822","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671253201","title":"Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2671253201","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671253201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"REVTORPYK (gedatolisib)   REVTORPYK (gedatolisib) vial and box  REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371842/0/en/celcuity-announces-that-revtorpyk-gedatolisib-is-now-commercially-available-in-the-united-states.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRET","BK4599","BK4203","LU1878469433.USD","LABU","BK4585","UBCP","BK4211","NVIB","BK4225","IDNA","BK4139","ALT","BK4588","GDOC","HR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671726206","title":"Satellos announces enrollment completed for BASECAMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2671726206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671726206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:15","pubTimestamp":1790766924,"startTime":"0","endTime":"0","summary":"Satellos (MSLE) Bioscience announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-announces-enrollment-completed-for-basecamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-announces-enrollment-completed-for-basecamp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","GDOC","IDNA","NVIB","MEDX","MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671206085","title":"Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671206085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671206085?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:15","pubTimestamp":1790766915,"startTime":"0","endTime":"0","summary":"Citigroup downgraded Moderna, Inc. ($MRNA) from Neutral/High Risk to Sell/High Risk after the biotech stock’s sharp two-month rally, arguing that o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/citi-downgrades-moderna-stock-after-222-rally-calls-oncology-expectations-unrealistic?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/citi-downgrades-moderna-stock-after-222-rally-calls-oncology-expectations-unrealistic?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4534","MRNX","BK4551","GNOM","BK4139","BK4548","BK4585","BK4532","BK4568","WDNA","BK4501","BK4533","LGHT","NVIB","MRNA","MRNY","XBIX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OZF.AU","ZYAU.AU","IMLC.AU","BK7096","GIVE.AU","BK4588","XKO.AU","VLS.AU","BBOZ.AU","MYX.AU","DACE.AU","VAP.AU","CUV.AU","E200.AU","BK4581","NVIB","XAO.AU","VAS.AU","IISV.AU","BK7508","BEAR.AU","GEAR.AU","BK7067","XJO.AU","EIGA.AU","QFN.AU","QRE.AU","IOZ.AU","XBI","IIGF.AU","BK4585","XBIX","SLF.AU","OZR.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671203699","title":"Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671203699","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671203699?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:10","pubTimestamp":1790763034,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-results-from-phase-3-asc40-304-ole-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-results-from-phase-3-asc40-304-ole-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","HYLG","SGMT","BK4139","MEDX","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671087702","title":"Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671087702","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671087702?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:00","pubTimestamp":1790762400,"startTime":"0","endTime":"0","summary":"In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patientsDenifanstat showed progressive ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371663/0/en/sagimet-announces-positive-full-52-week-results-from-license-partner-ascletis-phase-3-open-label-extension-clinical-trial-of-denifanstat-in-acne-presented-at-eadv-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","SD","HYLG","BK4213","GDOC","IGA","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671942228","title":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2671942228","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671942228?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:29","pubTimestamp":1790720940,"startTime":"0","endTime":"0","summary":"Chtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for theVIASKIN Peanut Patch in Children Aged 4-7 Years  TheBLAis supportedbyther","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3371452/0/en/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","BK4585","BK4588","LABU","GDOC","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671054242","title":"Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2671054242","media":"TIPRANKS","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671054242?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:10","pubTimestamp":1790712632,"startTime":"0","endTime":"0","summary":"Wells Fargo says admilparant protocol documents on EU clinical trials suggest liver safety issues in blinded Phase 3 data. While the firm says “we ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liver-safety-concerns-emerge-for-bristol-myers-admilparant-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liver-safety-concerns-emerge-for-bristol-myers-admilparant-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","LU0310800379.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","LU0980610538.SGD","LU0251131958.USD","FTXO","BK4504","LU0048573561.USD","LU0310799852.SGD","TFNS","LU0267386448.USD","LU1791807156.HKD","BK4126","LU1363072403.SGD","LU1894683264.USD","BK4585","LU0029864427.USD","LU0162691827.USD","LU0942090050.USD","LU1074936037.SGD","LU0052756011.USD","BK4559","LU1035773651.USD","LU1280957306.USD","LU0154236417.USD","GDOC","BK4582","LU1668664300.SGD","MEDX","NVIB","LU1506573853.SGD","LU0971096721.USD","PGF","IE00B19Z3581.USD","LU0320765489.SGD","LU0175139822.USD","LU2236285917.USD","KBWB","LU2361045086.USD","HYLG","IYF","BK4588","IDNA","LU0289960550.SGD","MYE","LU0211328371.USD","IE00B7SZLL34.SGD","IE000M9KFDE8.USD","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671117244","title":"New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2671117244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671117244?lang=en_us&edition=fundamental","pubTime":"2026-09-30 02:43","pubTimestamp":1790707417,"startTime":"0","endTime":"0","summary":"How hot are biotech stocks? One of the bellwethers for the industry, the iShares Biotechnology ETF ($IBB) (left chart), has gained over 24% year to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIS","XBIX","BK4588","NVIB","FXH","FDN","PTH","RXL","XLK","BIOY","FBT","IBB","BK4585","JHMH","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671949211","title":"NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2671949211","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671949211?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683200,"startTime":"0","endTime":"0","summary":"- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate ch","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370754/0/en/newamsterdam-pharma-doses-first-participant-in-phase-2b-spinoza-trial-evaluating-obicetrapib-in-preclinical-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","NVIB","BMED","CDR","BK4080","HYLG","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671116862","title":"Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2671116862","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671116862?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:49","pubTimestamp":1790682559,"startTime":"0","endTime":"0","summary":"The latest update is out from Invivyd ( ($IVVD) ). Invivyd, Inc. is a clinical-stage biotech company developing antiviral monoclonal antibodies, le...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671213179","title":"CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2671213179","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671213179?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:07","pubTimestamp":1790676452,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an update. CSPC Pharmaceutical Group has initiated a Phase Ib clinical trial in China for JMT20...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cspc-launches-phase-ib-trial-of-obesity-biologic-jmt206-in-china?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cspc-launches-phase-ib-trial-of-obesity-biologic-jmt206-in-china?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","GDOC","NVIB","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","LU2324357040.USD","BMED","MRNX","GNMX","BK4584","LFSC","IEIH","XLVX","BK4559","TEVA","RSPH","BK4596","MEDI","MRNY","BK4557","BK4588","BBP","GDOC","BK4585","IDNA","PINK","BK4007","SYNB","NVIB","LU1983299246.USD","LABU","TECB","BK4566","PSCH","IYH","TBXU","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}